Introduction to Xylazine

9.8.23

UPMC Addiction Medicine Lecture Day

Raagini Jawa MD, MPH, FASAM

Assistant Professor of Medicine, Department of General Internal Medicine Center for Research on Healthcare, University of Pittsburgh Clinical Harm Reduction Specialist, Grayken Center for Addiction rjawa@pitt.edu





Funding and Disclosures

- NIDA K12DA050607-03 University of Pittsburgh Collaboration in Addiction Training Scholars (PittCATS) Program
- 2023 CTSI Health Sciences Team Science Award
- 2023 Treetop Branch Pilot Award
- 2023 UPMC Magee CARES Research Award

I have no financial relationships to disclose with ineligible companies

Our sincere gratitude to the persons who use drugs, front-line harm reduction organizations, advocates, outreach clinicians, health department epidemiology and drug checking teams, researchers who have been contributing to the background for this presentation.



Learning Objectives


• Describe the trends of xylazine in U.S. illicit drug supply

- Recognize physiologic effects and clinical risks in persons using xylazine and appropriate harm reduction response
- Review clinical strategies for implementation for xylazine-harms



Xylazine (zie-luh-zeen)

- Central α2 adrenergic receptor agonist that causes central nervous system depression
- Has sedative, analgesic and muscle relaxant properties
- Names:
 - AnaSed, Rompun, XylaMed, Sedazine, Chanazine
 - Tranq, sleep-cut, Anastesia de caballo



Greene S et al. J Vet. pharm and therapeutics 1988



Rising national prevalence of xylazine

DEA Forensic Laboratory Identifications of Xylazine in exhibits by region

Region	2020	2021	% Increase
Northeast	346	556	61%
South	198	580	193%
Midwest	110	118	7%
West	77	163	112%

"Xylazine is making the deadliest drug threat our country has every faced, fentanyl, even deadlier," said Administrator Milgram. "DEA has seized xylazine and fentanyl mixtures in 48 of 50 States. The DEA Laboratory System is reporting that in 2022 approximately 23% of fentanyl powder and 7% of fentanyl pills seized by the DEA contained xylazine."

The Biden-Harris Administration's Actions to Address the Dangers of **Fentanyl Mixed with Xylazine** Designated Fentanyl Mixed with Xylazine as an **Emerging Threat Launched** First-of-Its-Kind National Response Plan for this Emerging Threat **Restricted** Unlawful Entry of Xylazine-Active Ingredients and Products Into the Country **Issued** Public Safety Alert on the Sharp Increase in Xylazine-Laced Fentanyl Trafficking **Convened** Leaders on Best-practices for Xylazine Testing, Wound Care, and Drug Treatment WHITEHOUSE.GOV

DEA. Joint intelligence Report October 2022



Xylazine + opioid are common BUT the concentrations of each vary

Date	Suspected	Drugs Identified		
9/13/2022	Dope	Fentanyl (18.4%), Xylazine (26.9%), 4-ANPP (10.6%) (OPI=1.84)		
9/21/2022	Dope	Fentanyl (6.6%), Xylazine (40.5%), 4-ANPP (1.0%), Procaine, Caffeine (OPI=0.69)		
9/21/2022	Dope	Fentanyl (7.7%), Xylazine (32.4%), para-Fluorofentanyl (0.3%), 4-ANPP (0.7%) (09/-0.2		
9/21/2022	Dope	Fentanyl (7.8%), Xylazine (26.6%), 4-ANPP (1.5%) (OPI=0.78)		
9/21/2022	Dope	Fentanyl (8.2%), Xylazine (58.4%), 4-ANPP (0.6%) (OPI=0.82)		
9/21/2022	Dope	Fentanyl (8.3%), Xylazine (26.3%), 4-ANPP (1.6%) (OPI-0.83)		
9/21/2022	Dope	Fentanyl (8.8%), Xylazine (30.1%), 4-ANPP (1.7%) [OPI-0.88]		
9/21/2022	Dope	Fentanyl (10.0%), Xylazine (36.8%), 4-ANPP (1.7%) (OPI=1.00)		
9/21/2022	Dope	Fentanyl (11.2%), Xylazine (43.7%), 4-ANPP (1.7%) (OPIELIZ)		
9/21/2022	Dope	Fentanyl (11.9%), Xylazine (38.0%), 4-ANPP (3.0%) (OPINID)		
9/21/2022	Dope	Fentanyl (13.2%), Xylazine (64.8%), 4-ANPP (2.0%) (OPI+1.32)		

DrugsData.org

ARM RE

Drug Checking Quarterly Report (Q3 2022): Philadelphia, PA



Patient's experience using xylazine-opioids vary

Many are UNAWARE that it is contaminating their drugs!

- 1. Extends the duration of sedation
- 2. May delay withdrawal
- 3. May assist in regulating sleep
- 4. Affordability

- 1. Dislike the sedating sensation
- 2. Worry it can cause:
 - An unintentional dependence
 - Risk for assault or injury when sedated
 - Negative clinical side effects

Reed, MR et al. DAD 2022 Jawa et al. Pending publication



UNC Street Drug Analysis Lab 500951

From Pittsburgh, Pennsylvania on 5/23/2023 Assumed to be xylazine, fentanyl

3 major substances detected:

- xylazine
- 4-ANPP
- fentanyl

500589

From Pittsburgh, Pennsylvania on 6/6/2023 Assumed to be fentanyl


2 major substances detected:

- xylazine
- fentanyl

University of

Pittsburgh


Pittsburgh: xylazine + opioids



ARM RE

Xylazine diagnostic testing

- Xylazine can be detected in blood and urine tests, BUT it is not routinely included in toxicology screens at UPMC
- Send out tests to specialty labs, BUT they take several days, have variable availability, and are less helpful to patients
- Need more research as unclear clinical utility and caution with interpretation, but may be helpful for surveillance





Xylazine test strips (XTS)

•Are a rapid visual immunoassay fo qualitative presumptive detection of xylazine

- A low-cost, high-impact harm-reduction strategy and patients are interested in testing their drugs prior to use
- •Compatible with most injectable, powder, or pill drugs
- Multiple commercially available AND range in cost and dilution ratios




University of

Pittsburgh

Magee Cares Award: Drs Hull, Jawa, Shang





How to use XTS

• Dissolve a tiny amount of product in water, dip the strip in the solution, wait a few minutes for the test result

- •We recommend to **only test for opioids**
- No validation studies in nonopioids



Xylazine toxidrome and effects

ACUTE EFFECTS:

- Prolonged sedation
- Blurred vision
- Dry mouth
- Low blood pressure
- Bradycardia
- Weak reflexes
- Disorientation
- Drowsiness
- Slurred speech
- Risk of overdose

CHRONIC EFFECTS

- Skin wounds
- Abnormal blood glucose
- Anemia

Kacinko SK et al. Journal of Analytical Toxicology 2022 Xiao, YF et al. BMC Anesthesiology 2013 Pending publication. Courtesy of N. Dasgupta 2023

ARM R



Xylazine withdrawal

- Not well-defined syndrome, can present with hypertension, anxiety, irritability, restlessness
- **Consider if protracted withdrawal symptoms despite on appropriate MOUD or adjunctive medications**
- Prophylaxis and treatment of xylazine withdrawal
 - Clonidine: 0.1mg PO q6-8h scheduled and titrated to effect, up to a max dose 0.3 mg PO Q8h
- Pain and opioid withdrawal management
 - Initiate on medications for opioid use disorder
 - Gabapentin 300-600 mg PO q8h + 300mg QHS or Pregabalin 50-100mg PO TID
 - Ketamine
 - Adjuncts: olanzapine, hydroxyzine, GABA agonists, dexmedetomidine

Penn CAMP. Best Practices for Management of Xylazine Withdrawal and Xylazine-related Overdose. 2023 Bettigole, et al, "Xylazine (Tranq) Exposure Among People Who Use Substances in Philadelphia." Ehrman-Dupre, R. et al. Journal Addiction Medicine 2022.



Prolonged sedation and loss of awareness

"I'm having more problems with the tranq then I am with the fentanyl down here. I have basically blackouts from the tranq. I lose days at a time. Like I'll lose four, five, six hours, and then when I come out of the blackout..."

At Risk for:

- Environmental Injury
- Extended immobility increases the risk for blood clots, soft tissue breakdown, muscle and nerve damage


Harm Reduction strategies:

- •Never use alone, safer consumption sites
- Rest in a safe place after using
- •Place in recovery position, avoid atypical positions

M.K. Reed, N.S. Imperato, J.M. Bowles et al. DAD 2022 Dasgupta N et al. Pending publication 2023.



Emerging Overdose Trends - Xylazine



Xylazine Noted as Contributing to Death



Introduction to Xylazine- Jawa, R 2023

6

ARM REDUCTION

Research Collaporative


Harm reduction strategies: xylazine- associated overdoses

- Dispel the myth of "naloxone resistant overdose"!
- People may not wake up for several hours after naloxone administration and this is not an indication to give more or higher doses of naloxone
- In an overdose
 - 1. Administer naloxone!!
 - 2. Place in recovery position
 - 3. Wait 2-3 minutes before administering another dose if needed
 - 4. Supportive field management until drug wears off and sedation resolves:
 - Rescue breathing, airway maneuvers, continuous pulse oximetry, supplemental O2
 - Rotating positions and massaging limbs

Hand supports



Xylazine OD patient handouts





Research Collaporative



WARNING

The following slides contains graphic images of drug use related wounds.



Introduction to Xylazine- Jawa, R 2023

ARM

Xylazine skin wounds

"Xylazine wounds are a whole other kind of...just horror...if there's xylazine in it, and if you miss [the vein], you were risking a really deep and necrotizing wound."



- Non-specific ulcer morphology, and is distinct from typical injection site infections
- Risk of wound supra-infection
- Anecdotal risk irrespective of route of administration
- Likely multifactorial mechanism

Reyes J. et al. Journal of Urban Health. 2012 Lopez et al. Addiction science and Clinical Practice 2015 Ehrman-Dupre, R. et al. JAM. 2021 Malayala et al. Cureus. 2022 Friedman, J et al. DAD 2022



Xylazine associated wounds can heal over time



Wei JJ, et al. JAAD Case Reports. 2023

ARM REDUC

Research Collaporative

Shared with patient permission Healthy Streets Outreach Program



Harm Reduction Strategies: Screening & Prevention

- ASK patients if they have had any about atypical wounds
- Educate patients on <u>RED flag symptoms</u>→
- Consider use of XTS and advise to seek alternate batch

• Fever or chills


- Skin turns dark or black
- Skin is red, hard, & hot to touch
- Thick, smelly yellow or green drainage
- Severe or worsening pain at wound site
- Pain & decreased ability to move joint
- Pieces of tissue falling off
- Exposed bone or tendon
- New numbness

Images Courtesy of M. Shang 2023



Framework for wound management

1) Evaluate for infection and need for antibiotics






Examples of wound care kits



Image courtesy of Jen Shinefeld 2023



Xylazine wound care patient handouts





Introduction to Xylazine- Jawa, R 2023

Research Coll

What can we do? Address Misinformation

- Xylazine is not naloxone resistant, it is simply not an opioid.
- Like fentanyl, there is **no known risk** to first responders from xylazine exposure.
- Xylazine does not cause "flesh eating" wounds and the **wounds are not contagious** to first responders.
- Sedation from xylazine will make people who use less able to respond and less able to follow directions.
- Words Matter! Xylazine is NOT a "zombie drug", and further stigmatizes individuals



What can we do? Educate and Refer




- Upcoming virtual training: 9/13/23 Grayken Center for Addiction TTA: addictiontraining.org
- Talk to your patients who use drugs about xylazine and screen for xylazine-harms
- Refer patients to get XTS: IM-REP, [Fall 2023 Magee, Latterman, and CPCDS]
- Refer patients for Xylazine Wound Care: UPMC IM-REP Clinic



What can we do?



- INNOVATE: Develop protocols and to address xylazine-related harms
- ADVOCATE:
 - To local health departments for safe drug supply, offer local drug checking centers, fund xylazine test strips
 - To medical examiners to universally screen for xylazine
- RESEARCH!





Raagini Jawa, MD, MPH, FASAM HRRC Principal Investigator

Assistant Professor of Medicine Division of General Internal Medicine Center for Research on Healthcare

Gary McMurtrie, BS HRRC Research Assistant Division of General Internal Medicine

Samia Ismail, BS HRRC Research Assistant Boston University School of Public Health MPH candidate

ARM REDUCTION Research Collaborative

Margaret Shang, MD HRRC Co-Investigator, Lead Medical Illustrator

Clinical Instructor of Medicine Division of General Internal Medicine ICRE Medical Education MS Program

Ariana Freund, BS HRRC Administrative Lead

Program Manager UPMC IM-REP, 2nd Ave Commons Clinic University of Pheonix MHA/MBA candidate

Olivia Studnicki HRRC Research Assistant University of Pittsburgh BS Chemistry candidate President Students for Sensible Drug Policy



Email: rjawa@pitt.edu

Thank You!!

- University of Pittsburgh
- Prevention Point Pittsburgh
- Grayken Center of Addiction
- Stephen Murray
- Dr. Nabarun Dasgupta
- Dr Ashish Thakrar
- Responding to Xylazine in the Drug Supply Part 1&2. National Harm Reduction Coalition Office Hours. 4/8/2022
- Sara Wallace-Keeshen, BSN, RN, Rachel McFadden, BSN, RN, CEN, & Rebecca Hosey, MPH, BSN, RN. Basics of Wound Care. Substance Use Response Guidance and Education. 9/2022.
- Claire Zagorski, MSc, LP. What we need to know about Xylazine. Be Well Texas ECHO. 10/6/22
- Dr. Joseph D'Orazio. Toxicity of Xylazine and How it impacts treatment for people who use drugs. COBRE on Opioids and Overdose. 6/16/22
- NASTAD Beyond the Alerts: Practical Guidance for Responding to Xylazine webinar. 2/21/2023
- Dr Ramsey. Learning Thursdays: Xylazine. NYS OASAS. 2/10/2023
- Jason Bienert. Experiences with Xylazine-related problems. From a Wound care nurse, Voices of Hope, Cecil & Hartford County, Maryland.
- Rebecca Hosey. Xylazine effects on wounds: Why and how we care. HRNA AIIRM. 1/10/2023

Please email us your experience and questions with xylazine!

Email: rjawa@pitt.edu

